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In add i t ion to i n h i b i t i n g t h e format ion of ang io ten­
s in II, chronic conver t ing e n z y m e i n h i b i t i o n m a y 
affect o ther b lood p re s su re m o d u l a t i n g factors. T h e 
influence of an 8 w e e k t r ea tmen t p h a s e w i t h Cilaza­
pr i l on t h e act ivi ty of t h e r en in -ang io t ens in -a ldos ­
t e rone a n d sympa the t i c n e r v o u s sys tems, t h e p r e s ­
sor react ivi ty to infused ang io tens in II or 
n o r e p i n e p h r i n e , t h e chronot ropic response to iso­
p ro te reno l , a n d b o d y s o d i u m a n d p l a s m a a t r ia l na ­
t r iu re t ic p e p t i d e concent ra t ions w a s assessed in 11 
n o r m a l subjects a n d 12 pa t i en t s w i t h essent ia l h y ­
pe r t ens ion . As compared to a 4 w e e k p lacebo phase , 
Cilazapril decreased ar te r ia l p r e s su re in b o t h s tudy 
g r o u p s (from 124/83 ± 9 /6 to 114/77 ± 9 / 5 m m Hg 
a n d from 143/102 ± 13 /7 to 137/96 ± 10/10 m m Hg; 
Ρ < .025); exchangeab le s o d i u m (—158 m m o l and , 
respect ively , —104 mmol) a n d u p r i g h t p l a s m a a l ­
dos te rone (—24% a n d —15%) also t e n d e d to fall. 
Hear t ra te , t he chronot ropic response to pos tu re or 
i soproterenol , p l a sma n o r e p i n e p h r i n e levels , t h e 
concen t r a t ion /p res so r response curve to n o r e p i ­
n e p h r i n e , p l a s m a at r ia l na t r iu re t i c pep t i de concen­
t ra t ion , p l a sma ang io tens in II a n d t h e responses of 
b lood p re s su re or p l a s m a a ldos te rone to ang io tens in 
II w e r e u n c h a n g e d after 8 w e e k s of Cilazapril. 
Plasma r e n i n act ivi ty increased (+175% to + 650%). 
These f indings indica te tha t t h e b lood p re s su re 
l o w e r i n g effect of Cilazapril i n t h e s table p h a s e of 
pharmacolog ica l i n t e rven t ion is not associated w i t h 
modif icat ions of s y m p a t h e t i c - d e p e n d e n t pressor r e ­
act ivi ty or ^ -adrenerg ic sensi t iv i ty . P lasma ang io ­
t ens in II concent ra t ion a n d ang io tens in I I -depen-
den t p a t h w a y s inc lud ing t h e pressor a n d 
a ldos te rone respons iveness to ang io tens in II a re also 
u n c h a n g e d . A m J H y p e r t e n s 1991;4:348-355 
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n o r e p i n e p h r i n e , essent ia l hype r t ens ion . 
The use of inhibitors of converting enzyme has become an established principle of antihyper­tensive pharmacotherapy, but the mechanisms relating converting enzyme inhibition to a de­
crease of arterial pressure remain unclear. Reduction of 
circulating angiotensin II (All) is the initial event . 1 
Under chronic conditions, the relationship between vari­
ations in arterial pressure and circulating All 
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is less close, 2 suggesting that additional mechanisms 
may be involved. Angiotensin II levels in tissues rather 
than in blood may determine arterial pressure . 3 Accu­
mulation of vasodilating kinins 4 or prostaglandins 5 may 
occur. Sympathet ic-dependent cardiovascular regula­
tion may be modified. 6 Moreover, the plasma levels of a 
pressor hormone are inversely related to the cardiovas­
cular pressor reactivity to t hem. 7 Therefore, a decrease 
of circulating All will result in a net depressor effect only 
in the absence of a full compensation by an incremented 
pressor sensitivity to AIL 
After the introduction of the first oral acting convert­
ing enzyme inhibitor, Captopril, more potent and longer 
acting substances, such as enalapril, were proposed for 
clinical use . 8 Cilazapril, one of the newer substances, 
has the characteristics of a nonsulfhydryl prodrug, ie, 
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after oral administration it is rapidly converted to the 
active metabolite, cilazaprilat. 9 Pharmacodynamic in­
vestigations in h u m a n s suggest that this drug is more 
potent and longer acting than both Captopril and enala­
p r i l 1 0 and does not accumulate with repeated adminis­
tration despite the long half-life. 1 1 In order to investigate 
further the mechanism of action of chronic converting 
enzyme inhibition, this long-acting compound was 
chosen; its s imultaneous effects on several blood pres­
sure modulat ing systems including the pressor reactiv­
ity to angiotensin II or norepinephrine were evaluated in 
normal subjects and patients with essential hyper ten­
sion. 
SUBJECTS A N D M E T H O D S 
Twenty-three subjects aged between 18 and 70 years 
were recruited for the study. They included 11 normal 
subjects (four women and seven men), aged 29 to 60 
years (mean ± SD age 38 ± 10 years), and 12 patients 
with essential hypertension (four women and eight 
men) , aged 26 to 58 years (mean age 45 ± 12 years) with 
a diastolic blood pressure between 95 and 115 m m Hg. 
The normal subjects were healthy volunteers without 
previous episodes of high blood pressure and with a 
blood pressure consistently < 140 /90 m m Hg through­
out the study. The presence of hypertension in the pa­
tients was defined by obtaining repeated blood pressure 
measurements of between 140 /90 and 180 /115 m m 
Hg, taken under outpatient conditions. Secondary 
forms of hypertension were excluded by the usual tests; 
no patient had malignant hypertension (hypertensive 
ret inopathy stages III-IV), edema, arrhythmia, renal 
failure (serum creatinine > 9 5 / /mol /L) or heart failure. 
All antihypertensive drugs and potassium supplements 
were discontinued at least 3 weeks before the study 
began. None of the women was taking hormonal con­
traceptives. Informed consent was obtained from all 
subjects and the study protocol was approved by the 
ethical committee of our institution. 
T r e a t m e n t P lan The subjects were instructed to con­
tinue eating a normal diet, avoiding very high or low 
sodium in takes . 1 2 A placebo (one tablet daily) was given 
over a period of 4 weeks and was then replaced by a 2.5 
mg dose of Cilazapril, given once daily at breakfast. 
After 2 weeks of treatment, the dose was increased to 5 
mg daily if diastolic blood pressure was not decreased to 
90 m m Hg. The duration of the whole treatment phase 
was 8 weeks. 
Blood Pressure , H o r m o n e s a n d Isoproterenol Test 
During therapy, subjects had their blood pressure and 
heart rate measured every 2 weeks, 24 to 26 h after their 
intake of the last Cilazapril dose, between 7:00 and 9:00 
AM, after 10 min rest in the supine position and after 
2 min in the standing position. During the 4 last days of 
the placebo and Cilazapril t reatment phases, the follow­
ing measurements were obtained. A 24 h urine collec­
tion was carried out to determine sodium, potassium, 
and creatinine excretion rates. Blood pressure (standard 
cuff and sphygmomanometer ; each value was the mean 
of three readings), heart rate, exchangeable sodium, and 
plasma sodium, potassium, calcium, phosphate , creati­
nine, uric acid, renin activity, angiotensin II (All), aldos­
terone, norepinephrine (NE), epinephrine, and atrial 
natriuretic peptide (ANP) were determined after an 
overnight fast and after 1 h of rest in the supine position 
(subjects took only the usual morning dose of placebo or 
C i l a z a p r i l ) . Blood pressure, heart rate, plasma renin ac­
tivity, All, aldosterone, NE, epinephrine, and A N P le­
vels were measured again after the subjects had spent 
60 min walking. After emptying the bladder, subjects 
rested in the supine position and an isoproterenol sensi­
tivity test was performed with bolus injections accord­
ing to our s tandard p rocedure . 1 3 ' 1 4 
N o r e p i n e p h r i n e a n d Ang io tens in II Infus ion In 
order to test the subjects' pressor or aldosterone respon­
siveness, NE and All were infused intravenously 1 to 3 
days after the isoproterenol test according to our stan­
dard p r o c e d u r e . 1 3 , 1 4 
Methodo logy Plasma and urinary sodium were mea­
sured by flame photometry. Creatinine, uric acid and 
calcium concentrations were measured by autoana-
lyzer, phosphate by colorimetric phosphomolybdate . 
Plasma renin activity, aldosterone, All, and A N P 
were determined by r a d i o i m m u n o a s s a y 1 5 - 1 8 and 
plasma NE and epinephrine concentrations were ob­
tained using a radioenzymatic m e t h o d , 1 9 as reported 
e l sewhere . 2 0 Exchangeable sodium was measured by 
isotope dilution technique using 2 4 N a . 2 1 Cardiovascular 
reactivity was analyzed by calculation of threshold and 
pressor d o s e s 1 3 , 1 4 and by deriving dose-response curves. 
The chronotropic isoproterenol dose was derived using 
the dose-response curve relating isoproterenol-induced 
increments of heart rate to the isoproterenol doses . 2 2 
Statistics Since the logarithmic transformation rather 
than the absolute values followed a Gaussian distribu­
tion, the natural logarithmic transformation of plasma 
renin activity, infused NE dosage, All or isoproterenol 
and pressor or threshold NE and All dosages, and 
chronotropic isoproterenol dosages were used for the 
statistical analysis. Statistical analysis included the 
paired Student 's two-tailed t test and the Wilcoxon test 
(comparison of paired values within groups), regression 
analysis, analyses of variance (comparison of values 
among the groups) and covariance (comparison of 
dose-response curves). 
RESULTS 
At the end of the placebo phase, normotensive and hy­
pertensive subjects did not differ significantly in mean 
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TABLE 1. CLINICAL AND BIOCHEMICAL FINDINGS BEFORE AND AFTER CILAZAPRIL IN NORMAL AND 
HYPERTENSIVE SUBJECTS (MEAN ± SD) 
Normal Subjects Essential Hypertension 
Placebo C i l a z a p r i l P lacebo C i l a z a p r i l 
Blood pressure, mm Hg 
supine 124/83 ± 9 / 6 114/77 ± 9 / 5 * 143/102 ± 13/7 137/96 ± 10/10* 
upright 120/86 ± 14/8 110/81 ± 10/6* 141/110 ± 13/8 136/104 ± 8 / 7 * 
Heart rate, beats/min 
supine 70 ± 14 67 ± 7 71 ± 8 71 ± 10 
upright 85 ± 1 4 88 ± 12 87 ± 12 82 ± 12 
Body weight, kg 73.1 ± 12.3 73.1 ± 12.4 75.5 ±11 .6 75.6 ±11 .9 
Exchangeable sodium, mmol 3140 ± 5 0 7 2982 ± 497 3008 ± 436 2904 ± 440 
Haematocrit, % 41.5 ±3 .85 40.7 ± 4 . 0 42.7 ± 5 . 2 42.7 ± 5 . 4 
Plasma sodium, mmol/L 140.6 ± 2 . 1 140 ± 1.8 140.2 ± 2 . 0 140.5 ± 2.3 
potassium, mmol/L 3.95 ± 0.27 4.03 ± 0.20 4.12 ±0 .25 4.15 ±0 .28 
calcium, mmol/L 2.34 ± 0.08 2.22 ± 0.08 2.36 ± 0.09 2.28 ± 0.08 
phosphate, mmol/L 1.17 ±0 .13 1.08 ±0 .13 1.01 ±0 .16 1.10 ±0 .18 
uric acid, //mol/L 263 ± 96 279 ± 107 258 ± 66 298 ± 68 
Creatinine clearance, mL/min 134 ± 20 137 ± 3 4 113 ± 2 2 111 ± 3 1 
Urinary sodium, mmol/24 h 170 ± 4 7 172 ± 3 9 137 ± 4 3 151 ± 5 9 
* Ρ < .025; t Ρ < .01 ν placebo values. 
age (38 ± 1 0 i ? 4 5 ± 1 2 years), body weight, exchange­
able sodium, heart rate, plasma or urinary electrolytes, 
and creatinine clearance (Table 1). 
The dose of Cilazapril was increased after two treat­
ment weeks in nine of 11 patients (mean dose 4.6 ± 
1.0 mg); in order to have a comparable dosage, the dose 
was also increased in six of the normal subjects (mean 
dose 3.8 ± 1 . 3 mg). 
As compared with the placebo phase , Cilazapril de­
creased supine and upright arterial pressure in both 
study groups (Table 1). Heart rate, body weight, plasma 
and urinary electrolytes, and creatinine clearance were 
unchanged (Table 1). Exchangeable sodium tended to 
decrease, but in the individual groups the change did 
not reach statistical significance. 
Ren in -Ang io tens in -Aldos t e rone Sys tem a n d React iv­
i ty to A l l As compared to placebo conditions, Cilaza­
pril caused a significant increase of supine and upright 
plasma renin activity and a fall of upright plasma aldos­
terone in the two study groups; supine plasma aldoster­
one decreased only in hypertensives (Table 2). Plasma 
All levels remained on average unchanged (Table 2). 
As compared to placebo conditions, supine, preinfu­
sion plasma All did not change significantly after Cila­
zapril in the two study groups while plasma aldosterone 
TABLE 2. RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM AND REACTIVITY TO ANGIOTENSIN II BEFORE 
AND AFTER CILAZAPRIL (MEAN ± SD) 
Normal Subjects Essential Hypertension 
Placebo C i l a z a p r i l P lacebo C i l a z a p r i l 
Plasma Reinin Activity, ng/mL-h 
supine 1.78 ± 0.7 7.69 ± 5.92* 1.81 ± 1.31 4.95 ± 3.94* 
upright 5.29 ± 2.03 31.54 ± 20.48t 4.20 ± 2.76 31.4 ± 34.5t 
Plasma Angiotensin II, pg/mL 
supine 6.1 ± 3.6 6.6 ± 2.0 8.7 ± 3.7 8.8 ± 4.7 
upright 13.1 ± 7.9 9.9 ± 3.2 16.3 ± 10.6 13.9 ± 7.6 
Plasma Aldosterone, ng/dL 
supine 7.2 ± 2.9 6.2 ± 1.5 7.8 ± 2.1 6.2 ± 1.5* 
upright 13.1 ± 7.9 9.9 ± 3.2* 16.3 ± 10.6 13.9 ± 7.6* 
Preinfusion plasma angiotensin II, pg/mL 7.7 ± 4.5 8.3 ± 1.9 10.5 ± 2.4 8.5 ± 3.6 
Angiotensin II threshold dose, ng/kg-min 1.12 ± 0.56 1.57 ± 1.45 0.83 ± 0.33 0.90 ± 0.62 
Angiotensin II pressor dose, ng/kg · min 12.12 ± 6.5 8.92 ± 5.13 6.33 ± 2.4 7.0 ± 4.2 
* Ρ < .05; t Ρ < -005 ν placebo. 
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tended to fall slightly al though not significantly (Figure 
1). After placebo, the pressor reactivity, as judged by the 
All pressor and threshold doses, was slightly, but not 
significantly, lower in hypertensive than in normal sub­
jects and did not change after Cilazapril in the two study 
groups (Table 2). After placebo, in normal subjects, the 
increase in systolic blood pressure during All infusion at 
the dose rate of 10 n g / k g · min (+ 22 ± 12 m m Hg) was 
associated with a significant (P < .005) decrease of heart 
rate (—9 ± 8 bea t s /min) ; in patients with essential hy­
pertension the All- induced increase of systolic blood 
pressure ( + 3 1 ± 11 m m Hg) was not accompanied by a 
decrease of heart rate (— 1 ± 6 bea t s /min) . The rela­
tionship between All-induced increases in blood pres­
sure and concomitant decrements of heart rate differed 
significantly between the two study groups (F = 21.2; 
Ρ < .01). After C i l a z a p r i l , heart rate decreased during 
All infusion in normal (+ 26 ± 14 m m Hg and —10 ± 6 
bea t s /min ) and hypertensive subjects ( + 2 9 ± 16 m m 
Hg and — 6 ± 4 bea t s /min ; Ρ < .01) and the relation­
ship between All- induced increments of blood pressure 
and decrements of heart rate did not differ between the 
two study groups (F = 0.48). 
The plasma All levels measured at the end of each All 
infusion dose rate correlated closely with the corre­
sponding dose rate; the correlation was similar after 
placebo and Cilazapril in normal subjects (respectively: 
r = 0.87; Ρ < .001; lny = 0.991nx + 2.76, and r = 0.87; 
Ρ < .001; lny = 0.991nx + 2.89) and hypertensive pa­
tients (r = 0.77; Ρ < .001; lny = 0.891nx + 3.20 and 
r = 0.87; Ρ < .001; lny = 1.061nx + 2.82). The relation­
ship between the All- induced increases in diastolic arte­
rial pressure and plasma All concentrations was not 
modified by Cilazapril as compared with placebo condi­
tions (F = 2.07 and 1.86; Ρ = NS) (Figure 1). 
After placebo, All caused a significant increase of 
plasma aldosterone in normal subjects and patients with 
essential hypertension (Figure 1). After Cilazapril, the 
plasma levels of aldosterone increased to a comparable 
extent during All infusion in normal subjects and in 
hypertensive patients. The relationship be tween plasma 
aldosterone and plasma All concentration obtained 
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FIGURE 1. Relationship between 
diastolic blood pressure or plasma al­
dosterone and plasma angiotensin II 
during angiotensin II infusion before 
and after Cilazapril in normal subjects 
(left panel) and patients with essential 
hypertension (right panel). Open sym­
bols indicate mean values after pla­
cebo; black symbols mean values after 
Cilazapril. Bars indicate SEM. The 
curves are not significantly different. 
5 0 100 2 0 0 4 0 0 
Plasma Angiotensin II, p g / m l 
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during ΑΠ infusion was not modified by Cilazapril as 
compared to placebo conditions in the two study groups 
(F = 0.03 and 0.86; NS) (Figure 1). 
Sympa the t i c N e r v o u s Sys tem At the end of the pla­
cebo phase, normal subjects and patients with essential 
hypertension did not differ significantly in supine and 
upright plasma NE and epinephrine levels as well as in 
NE threshold and pressor doses (Table 3). Cilazapril did 
not modify either plasma NE and epinephrine levels or 
the pressor reactivity to infused NE, as judged by the NE 
threshold and pressor doses (Table 3). 
Under placebo conditions, the increase in systolic 
blood pressure during NE infusion at the dose of 
200 n g / k g · min was associated with a significant de­
crease of heart rate in normal subjects (+ 30 ± 8 m m Hg 
and — 8 ± 6 bea t s /min ; Ρ < .01). Hypertensive patients 
responded to a lower NE dose rate (100 n g / k g · min) 
with a comparable increase of arterial pressure and de­
crease of heart rate ( + 3 3 ± 9 m m Hg and —6 ± 5 
bea t s /min ; Ρ < .025). After Cilazapril, the NE-induced 
increase in mean blood pressure was accompanied by a 
similar decrease of heart rate in the two study groups 
( + 3 3 ± 10 m m Hg and - 8 ± 6 b e a t s / m i n and + 3 6 ± 
14 m m Hg and — 5 ± 4 bea t s /min , respectively). The 
relationship between the NE-induced increases in arte­
rial pressure and the concomitant decrements of heart 
rate did not differ between normal and hypertensive 
subjects under placebo conditions and it was unaffected 
by Cilazapril (F = 0.06 to 0.46). 
Plasma NE concentration, measured at the end of 
each NE infusion step, correlated closely with the corre­
sponding NE infusion rates and correlations were simi­
lar in normal subjects before (r = 0.94; lny = 0.831nx + 
1.5; Ρ < .001) and after (r = 0.98; lny = 0.931nx + 1.09; 
Ρ < .001) Cilazapril; the corresponding correlations 
were also comparable in hypertensive patients (r = 
0.92; lny = 0 .831nx+1 .49 ; Ρ < .001 and r = 0.94; 
lny = 0 . 9 1 1 n x + 1 . 2 1 ; Ρ < .001). The concentration-
response curve of arterial pressure and plasma NE con­
centration was not modified by Cilazapril in the two 
study groups as compared to placebo conditions (Fig­
ure 2) ( F = 1 . 4 4 and 2.95). 
Atr ia l Nat r iu re t ic Pept ide At the end of the placebo 
phase, supine and upright plasma ANF levels were 
lower (P < .05) in normal subjects (27.5 ± 19.4 and 
18.6 ± 16.0 p g / m L ) than in hypertensive patients 
(52.5 ± 28.5 and 38.3 ± 20.5 pg /mL) . There was no 
change after Cilazapril, with a persistent elevation in 
hypertensives (30.5 ± 21.3 and 19.8 ± 13.3 p g / m L in 
normal subjects ν 62.5 ± 39.1 and 34.3 ± 15.1 p g / m L 
in hypertensive patients). 
Sensi t iv i ty to I soproterenol Chronotropic effects of 
isoproterenol, as judged by the mean threshold and 
chronotropic doses, were comparable between normal 
and hypertensive subjects (0.3 ± 0.3 and 1.6 ± 1.5 //g ν 
0.2 + 0.2 and 1.8 ± 1.3 //g). Both variables were un­
changed after Cilazapril (0.4 ± 0.7 and 1.3 ± 1.1 //g in 
normal subjects, 0.2 + 0.2 and 2.0 ± 1.5 //g in hyper­
tensive patients) (Figure 3). 
With respect to dose-response curves, the heart rate-
isoproterenol relationships were similar in normal and 
hypertensive subjects after placebo (Figure 3). After Ci­
lazapril, the dose-response curve was slightly, nonsig-
nificantly displaced to the right in normal subjects (F = 
3.47; Ρ = NS) and was unchanged in hypertensives 
(F = 0.002; Ρ = NS). 
Side Effects Side effects were not reported by normal 
and hypertensive subjects, except for the report of mild 
cough by one healthy man. The hematological and bio­
chemical control parameters did not change during the 
study, except for a transient slight increase of the serum 
aspartate and alanine aminotransferase in one normal 
subject. 
TABLE 3. PLASMA CATECHOLAMINES AND NOREPINEPHRINE INFUSION BEFORE AND AFTER 
CILAZAPRIL (MEAN ± SD) 
Normal Subjects Essential Hypertension 
Placebo Cilazapril Placebo Cilazapril 
Plasma Norepinephrine, ng/dL 
supine 21.2 ± 6.4 19.3 ± 6.7 23.8 ± 9.5 24 ± 9 
upright 41.9 ± 13.7 34.8 ± 7.4 41.4 ± 17 50.7 ± 24.5 
Plasma Epinephrine, ng/dL 
supine 3.1 ± 1.6 2.9 ± 2.2 3.5 ± 3.3 3.5 ± 3.2 
upright 6.6 ± 3.9 5.0 ± 2.8 6.0 ± 4.1 7.4 ± 6.8 
Preinfusion plasma angiotensin II, pg/mL 8.7 ± 5.0 7.1 ± 2.2 10.4 ± 3.0 8.0 ± 2.5 
Preinfusion plasma norepinephrine, ng/dL 20.5 ± 9.8 18.4 ± 2.8 24 ± 9.1 24.4 ± 7.7 
Norepinephrine threshold dose, ng/kg-min 51 ± 79 48 ± 39 25 ± 14 33 ± 35 
pressor dose, ng/kg · min 143 ± 58 190 ± 79 163 ± 80 206 ± 205 
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FIGURE 2. Relationship between 
mean blood pressure and plasma nor­
epinephrine during norepinephrine 
infusion before and after Cilazapril in 
normal subjects (left panel) and pa­
tients with essential hypertension 
(right panel). Open symbols indicate 
mean values after placebo; black sym­
bols mean values after Cilazapril. Bars 
indicate SEM. The curves are not sig­
nificantly different. 
DISCUSSION 
The findings of the present s tudy indicate that the blood 
pressure lowering effect of an 8 week converting en­
zyme inhibition with the long acting compound Cilaza­
pril was not accompanied by modifications of the physi­
ological relationship between the endogenous nor­
adrenergic activity and the cardiovascular pressor reac-
Normal Subjects Essential Hypertension 
Δ Heart Rate 
30-, bpm 
20 
10 
O Placebo 
• Cilazapril 
Δ Placebo 
• Cilazapril 
1 1 1 1 ι 1 1 1 1 
0.2 0 . 4 0.8 1.6 3.2 0.2 0 . 4 0.8 1.6 3.2 
Isoproterenol, ug 
FIGURE 3. Dose response curves for isoproterenol-induced in­
creases in heart rate before and after Cilazapril in normal subjects 
(left panel) and patients with essential hypertension (right panel). 
Open symbols indicate mean values after placebo; black symbols 
mean values after Cilazapril. Bars indicate SEM. The curves are 
not significantly different. 
tivity to NE. Despite concomitant renin activation and 
aldosterone suppression, as indices of effective convert­
ing enzyme inhibition, two angiotensin II-dependent 
pa thways , the cardiovascular pressor reactivity and the 
adrenal release of aldosterone, were unaltered. Plasma 
levels of ANF were also unchanged. On the other hand , 
a tendency for suppressed plasma aldosterone and body 
sodium depletion may identify two contributory factors 
in the hypotensive mechanism of converting enzyme 
inhibition. 
Cilazapril, given for 8 weeks, significantly decreased 
arterial pressure in both normal and hypertensive sub­
jects, wi thout modification of the heart rate, the chrono­
tropic response to assumption of the upright posture, 
isoproterenol injection or, as demonstra ted in a previous 
study, to exercise. 2 3 The decrease of heart rate during 
acute, NE-induced elevation of arterial pressure was 
also unchanged, pointing to an unaltered baroreflex sen­
sitivity. In our hypertensive patients, the bradycardie 
response to All infusion was found to be blunted after 
placebo and normal after Cilazapril. The meaning of this 
observation is unclear. A dissociation between a normal 
heart rate responsiveness to NE and a blunted response 
to All is not a feature of hypertensive patients and was 
not observed previously in our laboratory. 1 3 On the 
other hand , Cilazapril did not alter the heart rate re­
sponse to All in normal subjects, despite the significant 
decrease of arterial pressure. In single dose studies, Cila­
zapril did not modify heart rate, sympathetic nervous 
activity and baroreflex sensitivity, but enhanced para­
sympathetic activity, 2 4 suggesting a withdrawal of the 
vagolytic actions of AIL Similar findings were reported 
after administration of other compounds such as C a p t o ­
pril or ena lapr i l , 1 4 , 2 5 indicating a similar cardiovascular 
profile for these compounds . 
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Noradrenergic activity and pressor reactivity to NE 
did not change in both normal and hypertensive sub­
jects after Cilazapril. Plasma NE and epinephrine levels 
were reported to be unchanged after Captopril 2 6 ' 2 7 or 
enalapr i l . 2 8 The pressor effects to infused NE, studied 
after short- term converting enzyme blockade (up to 2 
weeks) was noted to be b lun t ed 2 9 or u n c h a n g e d . 3 0 , 3 1 A 
limited sensitivity of the pressor response curves with­
out concomitant measurements of the plasma NE con­
centration could, at least partly, explain these discrepan­
cies. After more prolonged treatment, the pressor 
reactivity remained unchanged in normal subjects but in 
patients with essential hypertension a decrease of the 
slope of the pressor response curve to NE was re­
por t ed . 2 8 In the latter investigation, the blunted pressor 
reactivity to NE emerged only at very high concentra­
tions of plasma NE, while at physiological or moder­
ately elevated levels the responsiveness of blood pres­
sure to NE was normal. 
Body sodium, measured in patients with essential or 
renovascular hypertension, was reported to be un­
changed after Captopril or enalapri l . 1 ' 8 In contrast, a 
slight decrease was reported in 16 hypertensive patients 
treated for 6 weeks with enalapri l . 2 8 In the present 
study, exchangeable sodium tended to decrease in both 
normal and hypertensive subjects. It appears possible 
that a decrease of plasma aldosterone may have in­
fluenced sodium metabolism. However, a fall in plasma 
aldosterone was not observed in all studies with con­
verting enzyme inhibitors, since after suppression in the 
early phase, plasma aldosterone tends to rise in the 
chronic phase of t rea tment . 3 2 This pat tern of adrenal 
response may reflect the complex regulation of aldos­
terone secretion, since in addition to All, other modulat­
ing factors such as sodium and potassium balance are 
potentially influenced by converting enzyme inhibi­
t ion. 1 
The profile of the renin-angiotensin-aldosterone sys­
tem after Cilazapril was characterized by unchanged All 
levels, a markedly stimulated plasma renin activity, and 
a tendency for decreased plasma aldosterone concen­
tration. The failure to detect a persistent decrement of 
circulating All during chronic converting enzyme inhibi­
tion with Cilazapril or other c o m p o u n d s 2 8 may be at least 
partly related to crossreactivity of high angiotensin I 
levels in the radioimmunoassay of AIL 1 O n the other 
hand , activation of angiotensin I may partly overcome 
the competitive inhibition of converting e n z y m e . 3 3 The 
association of unchanged plasma All levels and de­
creased plasma aldosterone levels may support the pos­
sibility of a dissociation in the renin-angiotensin-aldos­
terone axis. This may reflect the partly different 
regulation of the two hormones and has been reported 
under other circumstances, such as a rapid change in 
dietary sodium in take . 3 4 Unchanged plasma All levels 
were associated with unchanged pressor and adrenal 
responses to AIL Thus, it would appear that after 
chronic converting enzyme inhibition the renin-angio­
tensin system may be able to recover, at least partly, a 
physiological acute regulation of the pressor and aldos­
terone regulating pathways . This may also imply that 
under these circumstances the All receptor number and 
the receptor-agonist affinity are not modified. Previous 
data in the literature are consistent with this hypothesis; 
after acute blockade with converting enzyme there is an 
acute fall of plasma All with an enhanced response of 
blood pressure or plasma aldosterone to infused AIL 2 9 - 3 1 
Under more chronic conditions, 1 to 8 weeks of treat­
ment with Captopril, the pressor reactivity to All was not 
modi f ied . 1 4 , 3 5 After 6 weeks of treatment with enalapril, 
the acute aldosterone response to infused All was un­
changed in normal and hypertensive subjects . 2 8 
Plasma ANF concentration were significantly ele­
vated in the present group of patients with essential 
hypertension. This could not be explained by differ­
ences in age or renal function. Cilazapril did not alter 
plasma ANF levels in the two study groups. This sug­
gests that Cilazapril is an effective antihypertensive 
agent, with a cardiovascular profile comparable to that 
of other available converting enzyme inhibitors. Its 
mechanism of action may be partly related to sodium 
depletion and aldosterone suppression, but not to modi­
fications of sympathet ic-dependent pressure regula­
tion, atrial natriuretic peptide concentration, or All de­
pendent pa thways for acute blood pressure or 
aldosterone regulation. 
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